Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA

References

• Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA. 2008;105:4826–4831.
   Web of Science ®Google Scholar
• Zhang KJ, Li J, Meng WT, et al. Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo. Blood Cells Mol Dis. 2016;56:46–52.
   PubMed Web of Science ®Google Scholar
• Wang L. Study on absorption mechanism of lipophilic components of danshen and the method of enhance absorption. Chengdu: Sichuan University; 2006.
   Google Scholar
• Li SC, Liu JP, Zeng ZZ, et al. Study on the solubility and permeability of tanshinone II A and on the excipients increasing the solubility and permeability. Lishizhen Med Mater Med Res. 2008;19:1724–1726.
   Google Scholar
• Yan HM, Sun E, Cui L, et al. Improvement in oral bioavailability and dissolution of tanshinone IIA by preparation of solid dispersions with porous silica. J Pharm Pharmacol. 2015;67:1207–1214.
   PubMed Web of Science ®Google Scholar
• Jiang YR, Zhang ZH, Huang SY, et al. Enhanced dissolution and stability of Tanshinone IIA base by solid dispersion system with nano-hydroxyapatite. Pharmacogn Mag. 2014;10:332–337.
   PubMed Web of Science ®Google Scholar
• Li HL, Zhang ZY, Ma LL, et al. Preparation of tanshinone microemulsion and its absorption in rat intestine in situ. China J Chin Mater Med. 2007;32:1024–1027.
   Google Scholar
• Mellaerts R, Mols R, Jammaer JA, et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008;69:223–230.
   PubMed Web of Science ®Google Scholar
• McCarthy CA, Ahern RJ, Dontireddy R, et al. Mesoporous silica formulation strategies for drug dissolution enhancement: a review. Expert Opin Drug Del. 2016;13:93–108.
   PubMed Web of Science ®Google Scholar
• Dement’EvaO V, Senchikhin IN, Kartseva ME, et al. A new method for loading mesoporous silica nanoparticles with drugs: sol-gel synthesis using drug micelles as a template. Colloid J. 2016;78:586–595.
   Web of Science ®Google Scholar
• Sarkar A, Ghosh S, Chowdhury S, et al. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells. Biochim Biophys Acta. 2016;1860:2065–2075.
   PubMed Web of Science ®Google Scholar
• Varache M, Bezverkhyy I, Saviot L, et al. Optimization of MCM-41 type silica nanoparticles for biological applications: control of size and absence of aggregation and cell cytotoxicity. J Non-Ctryst Solids. 2015;408:87–97.
   Web of Science ®Google Scholar
• Laine AL, Price D, Davis J, et al. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilizing mesoporous silica and co-loaded HPMCAS. Int J Pharm. 2016;512:118–125.
   PubMed Web of Science ®Google Scholar
• Summerlin N, Qu Z, Pujara N, et al. Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol. Colloids Surf B Biointerfaces. 2016;144:1–7.
   PubMed Web of Science ®Google Scholar
• Jambhrunkar S, Karmakar S, Popat A, et al. Mesoporous silica nanoparticles enhance the cytotoxicity of curcumin. RSC Adv. 2014;4:709–712.
   Web of Science ®Google Scholar
• Jambhrunkar S, Qu Z, Popat A, et al. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica nanoparticles. J Colloid Interf Sci. 2014;434:218–225.
   PubMed Web of Science ®Google Scholar
• van Schooneveld MM, Vucic E, Koole R, et al. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 2008;8:2517–2525.
   PubMed Web of Science ®Google Scholar
• Wang LS, Wu LC, Lu SY, et al. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano. 2010;4:4371–4379.
   PubMed Web of Science ®Google Scholar
• Butler KS, Durfee PN, Theron C, et al. Protocells: modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery. Small. 2016;12:2173–2185.
   PubMed Web of Science ®Google Scholar
• Zhou XT, Zhang XW, Ye YH, et al. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int J Pharm. 2015;479:391–398.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Qi JP, Lu Y, et al. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine. 2014;10:167–176.
   PubMed Web of Science ®Google Scholar
• Jia LJ, Shen JY, Li ZY, et al. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs. Int J Pharm. 2012;439:81–91.
   PubMed Web of Science ®Google Scholar
• He QJ, Shi JL, Chen F, et al. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials. 2010;31:3335–3346.
   PubMed Web of Science ®Google Scholar
• Meng H, Wang M, Liu H, et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9:3540–3557.
   PubMed Web of Science ®Google Scholar
• Fu Q, Hargrove D, Lu XL. Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery. Nanomedicine. 2016;12:1951–1959.
   PubMed Web of Science ®Google Scholar
• Yefimova SL, Bespalova II, Grygorova GV, et al. Synthesis and characterization of mesoporous CaCO3@PSS microspheres as a depot system for sustained Methylene Blue delivering. Microporous Mesoporous Mater. 2016;236:120–128.
   Web of Science ®Google Scholar
• Barrett EP, Joyner LG, Halenda PP. The determination of pore volume and area distributions in porous substances. i. computations from nitrogen isotherms. J Am Chem Soc. 1951;73:373–380.
   Web of Science ®Google Scholar
• Lippens BC, de BJH. Studies on pore systems in catalysts: V. The t method. J Catal. 1965;4:319–323.
   Web of Science ®Google Scholar
• Khurana RK, Beg S, Burrow AJ, et al. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar system. Eur J Pharm Biopharm. 2017;121:42–60.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang F, Du C, et al. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Cancer Lett. 2017;402:213–224.
   PubMed Web of Science ®Google Scholar
• Mudakavi RJ, Raichur AM, Chakravortty D. Lipid coated mesoporous silica nanoparticles as an oral delivery system for targeting and treatment of intravacuolar Salmonella infections. RSC Adv. 2014;4:61160–61166.
   Web of Science ®Google Scholar
• Thommes M, Kaneko K, Neimark AV, et al. Physisorption of gases, with special reference to the evaluation of surface area and pore size distribution (IUPAC Technical Report). Pure Appl Chem. 2015;87:1051–1069.
   Web of Science ®Google Scholar
• Horkovics-Kovats S. Dissolution and coarsening of polydisperse, polymorph drug particles liberated from a disintegrating finished dosage form:theoretical considerations. Eur J Pharm Sci. 2016;91:265–277.
   PubMed Web of Science ®Google Scholar
• Han N, Wang Y, Bai JL, et al. Facile synthesis of the lipid bilayer coated mesoporous silica nanocomposites and their application in drug delivery. Microporous Mesoporous Mater. 2016;219:209–218.
   Web of Science ®Google Scholar
• Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82–85.
   Google Scholar
• Sengel-Turk CT, Hascicek C, Dogan AL, et al. Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line. J Drug Deliv Sci Tec. 2014;24:166–172.
   Web of Science ®Google Scholar
• Urama Ł, Szuster M, Filipowicz A, et al. Cellular uptake of glucoheptoamidated poly(amidoamine) PAMAM G3dendrimer with amide-conjugated biotin, a potential carrier of anticancer drugs. Bioorg Med Chem. 2017;25:706–713.
   PubMed Web of Science ®Google Scholar